Navigation Links
Lilly Receives NCQA Design Certification for Depression Care Management Program
Date:11/6/2007

INDIANAPOLIS, Nov. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has received Program Design Certification from the National Committee for Quality Assurance (NCQA) for its Tools that Empower(TM) Depression Care Management Program.

Tools that Empower(TM) Depression Care Management Program is designed for managed care organizations to assist in further driving the standard of patient care around Major Depressive Disorder (MDD). Lilly created the program in response to the growing population of patients diagnosed with MDD.

Developed by experts in MDD management, including practicing psychiatrists and psychologists, clinical research experts, managed care medical directors and mental health specialty physicians, Tools that Empower helps identify members with MDD and offers educational resources to support treatment. In addition, the program helps enroll members, perform clinical screening and clinical risk stratification; offers interventions based on member clinical risk; executes program satisfaction assessment and outcomes measurement; and provides a comprehensive list of MDD resources.

The foundation of this program is based upon the APA Standards of Care for major depressive disorder, the HEDIS(R) measure for Antidepressant Medication Management, and several other related, peer-reviewed articles.

NCQA certification is an indication that a disease management program has passed a rigorous review in a specific area, either program design, patient contact or disease management systems. According to NCQA, certification standards are purposely set high to encourage organizations to continuously enhance their quality.

"Disease management offers tremendous promise for improving the care received by the chronically ill," said Margaret E. O'Kane, president of NCQA. "By achieving NCQA DM Certification, an organization is showing that it is ready to provide specific services that can help fulfill that promise."

Offering relevant, non-branded interventions that are based on the most recent clinical research and findings is an example of how Lilly seeks to meet the needs of patients.

"Tools that Empower is part of Lilly's commitment to our customers to help reduce patient risk and create an environment of continuous improvement for patient care," said Jack Bailey, vice president, Lilly's Business to Business division. "The NCQA certification validates the helpful tools provided by the program."

Disease Management Certification is based on a review of disease management content - such as printed, electronic and in-person methods for working with patients and practitioners - according to clinical guidelines. NCQA has reviewed and certified Lilly's Program Design capability. For complete details on the scope of this review, visit http://www.lilly.com.

Lilly also offers several other NCQA Design Certified programs as part of its ongoing commitment to improving patient safety and quality. They include:

-- Tools That Empower(TM) Diabetes Management Program, a robust diabetes

disease management program that contains more than 20 best-in-class

tools and resources for care managers and diabetes program directors.

-- HealthInsights for Women, a disease management program that targets

women 30 years and older about disease risk factors, and inspires them

to make behavior changes that can lead to better health.

-- Health Evaluator for Lilly Partners (HELP), a comprehensive,

interactive online resource for patients that is flexible, customizable

and secure.

-- Expanding Views: Achieving more with ADHD, reinforces the importance

of providing follow-up care for patients with

attention-deficit/hyperactivity disorder (ADHD) based upon the HEDIS(R)

measure.

About NCQA:

NCQA is a private, non-profit organization dedicated to improving healthcare quality. NCQA is committed to providing healthcare quality information through the Web and the media in order to help consumers, employers and others make more informed healthcare choices.

Consumers can access an organization's NCQA Accreditation and Certification status and other information on healthcare quality on NCQA's Web site at http://www.ncqa.org, or by calling NCQA Customer Support at (888) 275-7585.

About Lilly:

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

HEDIS (Healthcare Effectiveness Data and Information Set) is a registered trademark of the National Committee for Quality Assurance. Tools that Empower is a trademark of Eli Lilly and Company.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
Breaking Medicine News(10 mins):